BR112012015656A2 - composições de pirroloquinolinil-pirrolidina-2,5-diona purificada e métodos para preparar e utilizar as mesmas - Google Patents

composições de pirroloquinolinil-pirrolidina-2,5-diona purificada e métodos para preparar e utilizar as mesmas

Info

Publication number
BR112012015656A2
BR112012015656A2 BR112012015656A BR112012015656A BR112012015656A2 BR 112012015656 A2 BR112012015656 A2 BR 112012015656A2 BR 112012015656 A BR112012015656 A BR 112012015656A BR 112012015656 A BR112012015656 A BR 112012015656A BR 112012015656 A2 BR112012015656 A2 BR 112012015656A2
Authority
BR
Brazil
Prior art keywords
dione
methods
quinolin
pyrrolo
indol
Prior art date
Application number
BR112012015656A
Other languages
English (en)
Inventor
Christopher A Lee
David P Reed
Jian-Xie Chen
John C Kane
Martin P Redmon
Neil R Barnes
Original Assignee
Arquile Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arquile Inc filed Critical Arquile Inc
Publication of BR112012015656A2 publication Critical patent/BR112012015656A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

composições de pirroloquinolinil-pirrolidina-2,5-diona purificada e métodos para preparar e utilizar as mesmas. a presente invenção refere-se a um polimorfo de forma 1 e forma 2 de (-)-trans-3-(5,6-diidro-4h-pirrolo[3,2,1-ij] quinolin-1-il)-4-(1h-indol-3-il)pirrolidina-2,5-diona. a presente invenção também se refere aos compostos de (-)-trans-3-(5,6-diifro-4h-pirrolo [3,2,1-ij]quinolin-1-il)-4-(1h-indol-3-il) pirrolidina-2,5-diona tendo uma pureza quiral maior do que 99%, e aos métodos de preparação destes compostos. a presente invenção também se refere ás composições farmacêuticas que compreendem estes compostos de (-)-trans-3-(5,6-diidro-4h-pirrolo [3,2,1-ij] quinolin-1-il)-4-(1h-indol-3-il) pirrolidina-2,3-diona. a presente invenção proporciona métodos de tratar um distúrbio proliferativo de células, tal como um câncer, por administração a um paciente que necesita deles de uma quantidade terapeuticamente efeita de uma composição co0mpreendendo a (-)-trans-3-(5,6-diidro-4h-pirrolo [3,2,1-ij] quinolin-1-il)-4-(1h-indol-3-il) pirrolina-2, 5-diona tendo uma pureza quiral maior do que 99% ou um polimorfo de forma 1 e forma 2 de (-) trans-3-(5,6-diidro-4h-pirrolo [3,2,1-ij] quinolin-1-il)-4-(1h-indol-3-il) pirrolina-2, 5-diona.
BR112012015656A 2009-12-23 2010-12-21 composições de pirroloquinolinil-pirrolidina-2,5-diona purificada e métodos para preparar e utilizar as mesmas BR112012015656A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23
PCT/US2010/061625 WO2011079142A2 (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Publications (1)

Publication Number Publication Date
BR112012015656A2 true BR112012015656A2 (pt) 2016-05-10

Family

ID=44188284

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015656A BR112012015656A2 (pt) 2009-12-23 2010-12-21 composições de pirroloquinolinil-pirrolidina-2,5-diona purificada e métodos para preparar e utilizar as mesmas

Country Status (19)

Country Link
US (3) US8552192B2 (pt)
EP (2) EP2515904A4 (pt)
JP (2) JP2013515737A (pt)
KR (2) KR101669707B1 (pt)
CN (2) CN104910159A (pt)
AU (2) AU2010336533B9 (pt)
BR (1) BR112012015656A2 (pt)
CA (1) CA2785503A1 (pt)
CO (1) CO6561823A2 (pt)
HK (1) HK1215025A1 (pt)
MX (1) MX2012007259A (pt)
MY (1) MY156701A (pt)
NZ (2) NZ600800A (pt)
PH (1) PH12014500310A1 (pt)
RU (1) RU2556205C2 (pt)
SG (1) SG181927A1 (pt)
TW (3) TWI557125B (pt)
WO (1) WO2011079142A2 (pt)
ZA (1) ZA201204759B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1846406T3 (pl) * 2005-02-09 2011-04-29 Arqule Inc Pochodne imidowe kwasu maleinowego, kompozycje farmaceutyczne i sposoby leczenia nowotworów
AU2010336533B9 (en) * 2009-12-23 2015-10-08 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
JP6073310B2 (ja) * 2011-07-07 2017-02-01 アーキュール，インコーポレイティド ピロロキノリニル−ピロリジン−２，５−ジオン製剤及びその調製方法及び使用方法
EP2841069A4 (en) * 2012-04-23 2015-09-02 Arqule Inc HIGHLY PYRROLOCHINOLINYL-PYRROL-2,5-DION AND PYRROLOCHINOLINYL-PYRROLIDIN-2,5-DION AND METHOD FOR THE PRODUCTION THEREOF
JP2016527227A (ja) * 2013-07-16 2016-09-08 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドトロメタミン塩の新規な結晶形
PT3665176T (pt) * 2017-08-11 2024-03-13 Actuate Therapeutics Inc Formas sólidas de 3-(5-fluorobenzofurano-3-il)-4-(5-metil-5h[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
IL307471A (en) * 2021-04-07 2023-12-01 Ur 1 Therapeutics Inc URAT1 inhibitor, pharmaceutical preparations and their uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
US6867198B2 (en) * 1999-12-16 2005-03-15 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
EP1527034B1 (en) * 2002-07-31 2006-01-04 Firmenich Sa A process for the optical resolution of a precursor of sclareolide
JP2008512496A (ja) * 2004-09-10 2008-04-24 ワイス １，３，４，９−テトラヒドロピラノ［３，４−ｂ］インドール誘導体の大規模実施可能な合成方法
PL1846406T3 (pl) * 2005-02-09 2011-04-29 Arqule Inc Pochodne imidowe kwasu maleinowego, kompozycje farmaceutyczne i sposoby leczenia nowotworów
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
CN101801961B (zh) 2007-06-22 2014-09-24 艾科尔公司 吡咯烷酮、吡咯烷-2,5-二酮、吡咯烷和硫代琥珀酰亚胺衍生物、组合物以及治疗癌症的方法
JP5490688B2 (ja) * 2007-06-22 2014-05-14 アークル インコーポレイテッド 癌の治療のためのインドリルピロリジン
AU2010336533B9 (en) * 2009-12-23 2015-10-08 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
EP2841069A4 (en) * 2012-04-23 2015-09-02 Arqule Inc HIGHLY PYRROLOCHINOLINYL-PYRROL-2,5-DION AND PYRROLOCHINOLINYL-PYRROLIDIN-2,5-DION AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
EP2515904A2 (en) 2012-10-31
SG181927A1 (en) 2012-07-30
CN104910159A (zh) 2015-09-16
KR20120113760A (ko) 2012-10-15
WO2011079142A2 (en) 2011-06-30
JP2013515737A (ja) 2013-05-09
US8871933B2 (en) 2014-10-28
KR20160121602A (ko) 2016-10-19
MY156701A (en) 2016-03-15
ZA201204759B (en) 2014-03-26
CO6561823A2 (es) 2012-11-15
MX2012007259A (es) 2015-05-15
TW201141865A (en) 2011-12-01
AU2010336533A1 (en) 2012-07-12
EP3081567A3 (en) 2016-11-16
AU2010336533B9 (en) 2015-10-08
TW201542546A (zh) 2015-11-16
NZ628087A (en) 2016-02-26
JP2016041712A (ja) 2016-03-31
WO2011079142A3 (en) 2011-11-24
AU2015243015A1 (en) 2015-11-05
TW201643163A (zh) 2016-12-16
AU2015243015B2 (en) 2017-02-02
RU2012131344A (ru) 2014-01-27
CN102834097A (zh) 2012-12-19
EP3081567A2 (en) 2016-10-19
US20140031551A1 (en) 2014-01-30
PH12014500310A1 (en) 2015-09-28
CA2785503A1 (en) 2011-06-30
RU2556205C2 (ru) 2015-07-10
TWI506026B (zh) 2015-11-01
HK1215025A1 (zh) 2016-08-12
AU2010336533B2 (en) 2015-09-10
NZ600800A (en) 2014-10-31
KR101669707B1 (ko) 2016-10-27
US20160024076A1 (en) 2016-01-28
US8552192B2 (en) 2013-10-08
TWI557125B (zh) 2016-11-11
EP2515904A4 (en) 2013-07-03
CN102834097B (zh) 2015-06-17
US9499540B2 (en) 2016-11-22
US20110160242A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
BR112012015656A2 (pt) composições de pirroloquinolinil-pirrolidina-2,5-diona purificada e métodos para preparar e utilizar as mesmas
PH12015501678A1 (en) Inhibitors of influenza viruses replication
NZ600430A (en) Spiro-oxindole mdm2 antagonists
TN2012000265A1 (en) Triazolopyridines
WO2010039762A3 (en) Pharmaceutical compositions comprising boronic acid compounds
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
MX343383B (es) Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona.
WO2009128918A8 (en) Combination therapy using a soluble hyaluronidase and a bisphosphonate
MX2013006846A (es) Inhibidores de la replicacion de los virus de la influenza.
EA201200519A1 (ru) Стабилизированные жидкие и лиофилизированные композиции adamts13
WO2010093789A3 (en) A composition comprising (-) -trans-3- (5, 6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-l-yl)-4-(lh-indol-3-yl) pyrrolidine- 2, 5-dione in combination with a second anti-proliferative agent
JO2831B1 (en) Quinclidine carbonate derivatives and pharmaceutical compounds
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
UA99787C2 (en) Lactams as beta secretase inhibitors
MX2012014918A (es) Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
AR084832A1 (es) Derivado cristalino de oxazina
MX2010009147A (es) Derivados de pirrolidinilo y usos de los mismos.
ATE522531T1 (de) Indolylpyrrolidine zur behandlung von krebs
UA110245C2 (en) 7-(heleroaryl-amino)-6,7,8,9-letrahydropyrido[1,2-a]indol acetic acid derivatives and their application as prostaglandin d2 receptor modulators
MX2015006871A (es) Proceso de cristalizacion de derivados de indoles triciclicos.
WO2009109973A3 (en) Compounds and methods of treating obesity

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 8A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30/10/2018.